EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A New Survey about Dual-Acting PARP/COX-2 Inhibitors as Cancer Chemopreventive Agents

Mohammad Ismail Mahboubi Rabbani iD, Ali Aliabadi iD, Leila Bayat, Mahdokht Jafari, Amir Hossein Bagheri, Sarah Shateri, Rahil Hakimimofrad, Maryam Bayanati iD, Afshin Zarghi iD

Iranian Journal of Pharmaceutical Research · 26.05.2026 · 25 (1)

DOI: 10.5812/ijpr-169140 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 26.05.2026. Verfasst von Mohammad Ismail Mahboubi Rabbani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, School of Pharmacy and Pharmaceutical Sciences, Islamic Azad University, Tehran, Iran. Die Arbeit nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Poly(ADP-ribose) polymerase (PARP) is a key enzyme involved in DNA replication. Studies have shown that this enzyme plays a pivotal role in apoptosis and DNA damage repair. Excessive PARP activity, particularly that of PARP-1, may also lead to uncontrolled cellular growth and proliferation, thereby predisposing to tumor development. Similar effects have been observed with the overexpression of cyclooxygenase-2 (COX-2) in cancer development. In this review, our primary objective is to provide a concise and comprehensive structure–activity relationship to guide the design of compounds with dual inhibitory activity against PARP and COX-2. On the basis of this relationship, this review aims to support the development of novel compounds with potent inhibitory activity against PARP-1, as well as the design of dual PARP-1/COX-2 inhibitors. Evidence Acquisition: A comprehensive literature search was conducted to identify relevant studies on the design, synthesis, and biological evaluation of novel PARP and PARP-1 inhibitors, as well as dual-acting PARP-1/COX-2 inhibitors. Electronic databases, including Scopus, ScienceDirect, and Google Scholar, were systematically searched. Research articles published in English up to the most recent available date were considered. Studies were screened for relevance, clarity, and compliance with recognized molecular design guidelines. The collected information was analyzed and synthesized to provide an overview of the current state of PARP-1/COX-2 inhibitor synthesis approaches and design trends.

Results

Based on the review findings, the use of PARP-1/COX-2 dual inhibitors may be considered a viable therapeutic approach for targeting two interconnected pathways involved in cancer development. Dual-acting agents provide an opportunity to enhance anticancer efficacy and reduce resistance to malignancy. Moreover, preclinical studies have demonstrated synergistic effects. Notably, there are substantial similarities between the SAR of single- and dual-acting PARP-1/COX-2 inhibitors. In addition, polycyclic core structures could be used to guide the design of these compounds. Furthermore, these polycyclic structures may exhibit other important antineoplastic properties, such as inhibition of topoisomerase II (TPO-II).

Conclusions

In summary, to provide a more comprehensive review of the design and synthesis of novel chemical compounds as COX-2/PARP-1 dual inhibitors, additional compounds must be developed. Moreover, further clinical development and evaluation are required to improve their pharmacological properties and confirm their safety and efficacy in clinical settings.

Schlagwörter

Stichwörter der Autor:innen

COX-2 EnzymeDual InhibitorsPARP InhibitorThe Cancer Genome Atlas

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, School of Pharmacy and Pharmaceutical Sciences, Islamic Azad University, Tehran, Iran.
  • School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Mohammad Ismail Mahboubi Rabbani, Ali Aliabadi, Maryam Bayanati, Afshin Zarghi

Zitieren

APA

Ismail Mahboubi Rabbani, M., Aliabadi, A., Bayat, L., Jafari, M., Bagheri, A. H., Shateri, S., Hakimimofrad, R., Bayanati, M., & Zarghi, A. (2026). A New Survey about Dual-Acting PARP/COX-2 Inhibitors as Cancer Chemopreventive Agents. Iranian Journal of Pharmaceutical Research, 25(1). https://doi.org/10.5812/ijpr-169140

Vancouver

Ismail Mahboubi Rabbani M, Aliabadi A, Bayat L, Jafari M, Bagheri AH, Shateri S, et al. A New Survey about Dual-Acting PARP/COX-2 Inhibitors as Cancer Chemopreventive Agents. Iranian Journal of Pharmaceutical Research. 2026;25(1). doi:10.5812/ijpr-169140

BibTeX
@article{IsmailMahboubiRabbani2026,
  author = {Ismail Mahboubi Rabbani, Mohammad and Aliabadi, Ali and Bayat, Leila and Jafari, Mahdokht and Bagheri, Amir Hossein and Shateri, Sarah and Hakimimofrad, Rahil and Bayanati, Maryam and Zarghi, Afshin},
  title = {A New Survey about Dual-Acting PARP/COX-2 Inhibitors as Cancer Chemopreventive Agents},
  journal = {Iranian Journal of Pharmaceutical Research},
  year = {2026},
  volume = {25},
  number = {1},
  doi = {10.5812/ijpr-169140}
}
Kostenlos starten →